Jiangxi Kvvit Pharmaceutical Co., Ltd. clinical trials

A subsidiary of Qingfeng Pharmaceutical Group Co., Ltd.

The registry lists 7 studies whose lead sponsor is Jiangxi Kvvit Pharmaceutical Co., Ltd.. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 5, 2026.

Studies

Recruiting first, then most recently updated. Showing 7 of 7. All Qingfeng Pharmaceutical Group Co., Ltd. studies →

• Study of Single and Multiple Ascending Doses of KR23343 in Healthy Adult ParticipantsRecruitingNCT07409922Phase 1

  Sponsor listed in the registry: Jiangxi Kvvit Pharmaceutical Co., Ltd.

• Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D MutationNot yet recruitingNCT07689539Phase 3

  Sponsor listed in the registry: Jiangxi Kvvit Pharmaceutical Co., Ltd.

• Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D MutationNot yet recruitingNCT07656376Phase 2/3

  Sponsor listed in the registry: Jiangxi Kvvit Pharmaceutical Co., Ltd.

• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KR25102 in Healthy VolunteersNot yet recruitingNCT07618156Phase 1

  Sponsor listed in the registry: Jiangxi Kvvit Pharmaceutical Co., Ltd.

• A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult SubjectsNot yet recruitingNCT07585383Phase 1

  Sponsor listed in the registry: Jiangxi Kvvit Pharmaceutical Co., Ltd.

• Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne VulgarisNot yet recruitingNCT07345390Phase 2

  Sponsor listed in the registry: Jiangxi Kvvit Pharmaceutical Co., Ltd.

• A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for SuspensionNot yet recruitingNCT07113392Phase 3

  Sponsor listed in the registry: Jiangxi Kvvit Pharmaceutical Co., Ltd.